- Home
- TMHC vs LEGN Comparison
TMHC vs LEGN Comparison
Compare TMHC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMHC | LEGN |
|---|---|---|
| Founded | 1936 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.9B |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TMHC | LEGN |
|---|---|---|
| Price | $64.72 | $18.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $78.38 | $63.46 |
| AVG Volume (30 Days) | 1.1M | ★ 2.2M |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.77 | N/A |
| Revenue | ★ $4,762,059,000.00 | N/A |
| Revenue This Year | N/A | $67.72 |
| Revenue Next Year | $9.17 | $43.82 |
| P/E Ratio | $8.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $51.90 | $16.24 |
| 52 Week High | $72.27 | $45.30 |
Technical Indicators
Market Signals| Indicator | TMHC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.23 | 45.49 |
| Support Level | $60.11 | $16.24 |
| Resistance Level | $65.76 | $23.68 |
| Average True Range (ATR) | 2.05 | 0.91 |
| MACD | -0.32 | 0.29 |
| Stochastic Oscillator | 15.15 | 29.91 |
Price Performance
Historical ComparisonAbout TMHC Taylor Morrison Home Corporation
Taylor Morrison Home Corp is an American residential construction company engaged in residential homebuilding and the development of lifestyle communities. It designs, builds, and sells single and multi-family detached and attached homes in traditionally high growth markets for entry level, move-up, and resort lifestyle buyers. The company has four reportable segments: East, Central, West, and Financial Services. The majority of the company's revenue is derived from its West Segment.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.